CryoPort, Inc. $CYRX Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 37.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,498,774 shares of the company’s stock after purchasing an additional 408,263 shares during the period. Assenagon Asset Management S.A. owned 2.99% of CryoPort worth $14,208,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its stake in shares of CryoPort by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after acquiring an additional 1,557 shares during the last quarter. Avanza Fonder AB lifted its stake in shares of CryoPort by 31.4% in the 2nd quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock valued at $81,000 after purchasing an additional 2,601 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of CryoPort by 299.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock worth $27,000 after acquiring an additional 2,729 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of CryoPort by 13.8% in the 1st quarter. MetLife Investment Management LLC now owns 24,641 shares of the company’s stock valued at $150,000 after buying an additional 2,980 shares during the period. Finally, State of Wyoming grew its holdings in shares of CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after purchasing an additional 3,301 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Insiders Place Their Bets

In other CryoPort news, Director Ramkumar Mandalam sold 11,570 shares of the business’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the sale, the director owned 80,758 shares in the company, valued at $806,772.42. The trade was a 12.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on CYRX shares. Needham & Company LLC upped their target price on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. UBS Group upped their price objective on CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research note on Wednesday, November 5th. BTIG Research boosted their target price on CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.83.

CryoPort Stock Down 0.2%

Shares of NASDAQ CYRX opened at $9.42 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77. The stock’s 50-day simple moving average is $9.38 and its 200-day simple moving average is $8.60. The firm has a market cap of $471.66 million, a price-to-earnings ratio of 8.05 and a beta of 1.51. CryoPort, Inc. has a 1 year low of $4.58 and a 1 year high of $11.44.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The firm had revenue of $44.23 million for the quarter, compared to analysts’ expectations of $41.22 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. As a group, equities analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.